Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

AIMS: The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600–mutant tumours. METHODS: Part 1 of this phase 1, multicentre, 2‐part study (BRF113773/NCT01738451) assessed safety/tolerability of dabrafenib 225 or 300 mg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Nebot, Noelia, Arkenau, Hendrik‐Tobias, Infante, Jeffrey R., Chandler, Jason C., Weickhardt, Andrew, Lickliter, Jason D., Sarantopoulos, John, Gordon, Michael S., Mak, Gabriel, St‐Pierre, Annie, Tang, Lihua, Mookerjee, Bijoyesh, Carson, Stanley W., Hayes, Siobhan, Grossmann, Kenneth F.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Drug Safety
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867134/
https://ncbi.nlm.nih.gov/pubmed/29243287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13488
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars